Researchers conducted a case-control study to examine the associations between polygenic risk scores for schizophrenia and other mental disorders with the development of cannabis use disorder.
The investigators noted that “modifications in brain circuitry in service of developing more complex brain functionality in humans may have potentially also shaped aspects of human-specific brain dysfunction.
Overall, no significant relationships between task performance and gray matter volume were observed in the clinical high-risk group.
Prior research has demonstrated a link between schizophrenia and risk factors for lung cancer, particularly smoking, obesity, physical inactivity, and metabolic disorders.
Adverse cardiometabolic outcomes were more commonly observed among patients from black and ethnic minority groups compared with white patients.
Currently, there is no FDA-approved therapy to treat the negative symptoms of schizophrenia.
The application includes data from the ENLIGHTEN-1 and ENLIGHTEN-2 studies, in which treatment with the combination therapy was compared with placebo or olanzapine monotherapy in patients with schizophrenia.
The relationship between internalizing symptoms and psychotic-like experiences was similar for probable depression (OR, 1.08; 95% CI, 1.03-1.14; P =.003) and anxiety disorder (OR, 1.11; 95% CI, 1.05-1.17; P <.001).
According to the researchers, other published data suggest that visual deprivation causes increases in NMDAR-dependent cortical excitability.
Greater severity of depressive symptoms was significantly associated with increased severity of positive (P =.002) and negative (P =.003) schizophrenia symptoms.
